Alphabet on Track for Longest Winning Streak Since April 2019 — Data Talk
Alphabet Inc. Class A (GOOGL) is currently at $164.55, up $0.96 or 0.59%
--Would be highest close since Aug. 27, 2024, when it closed at $164.68
--Currently up nine consecutive days; up 10.69% over this period
--Longest winning streak since April 23, 2019, when it rose for nine straight trading days
--Best nine day stretch since the nine days ending April 26, 2024, when it rose 11.04%
--Up 0.72% month-to-date; on pace for best month since June 2024, when it rose 5.59%
--Up 17.8% year-to-date
--Down 13.93% from its all-time closing high of $191.18 on July 10, 2024
--Up 25.51% from 52 weeks ago (Sept. 25, 2023), when it closed at $131.11
--Down 13.93% from its 52-week closing high of $191.18 on July 10, 2024
--Up 34.69% from its 52-week closing low of $122.17 on Oct. 27, 2023
--Traded as high as $165.49; highest intraday level since Aug. 29, 2024, when it hit $165.97
--Up 1.16% at today's intraday high
--10th most active stock in the Nasdaq 100 today
All data as of 9:51:02 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 23, 2024 10:08 ET (14:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks